• Explore /
  • Poster
  • / A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).

A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Tawesak Tanwandee

Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Tawesak Tanwandee , Wattana Sukeepaisarnjaroen , Stephen Lam Chan , SuPin Choo , Guohong Han , Virote Sriuranpong , Hongming Pan , Thomas Cheung Yau , Zhenggang Ren , Jian-Ming Xu , Bin Peng , Takami Saji , Yongjian Sun , Alan Huang , Luigi Manenti , Shukui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01737827

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4074)

DOI

10.1200/JCO.2016.34.15_suppl.4074

Abstract #

4074

Poster Bd #

66

Abstract Disclosures

Similar Posters

First Author: Tony S. K. Mok

Poster

2014 ASCO Annual Meeting

Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.

Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.

First Author: Yung-Jue Bang

First Author: Min Yuan

First Author: Baojiang Liu